PredxBio, the leading company in Spatial Biology and Explainable AI for predicting the progression of disease has announced the appointment of Brad Spitz, MBA, as its Chief Commercial Officer. In this role, Brad will drive the company's commercial growth strategy, lead global sales and business development efforts, and further expand PredxBio's presence in the biopharma industry.
PITTSBURGH, June 7, 2023 /PRNewswire-PRWeb/ -- PredxBio, the leading company in Spatial Biology and Explainable AI for predicting the progression of disease, has announced the appointment of Brad Spitz, MBA, as its Chief Commercial Officer. In this role, Brad will drive the company's commercial growth strategy, lead global sales and business development efforts, and further expand PredxBio's presence in the biopharma industry.
Dusty Majumdar, PhD, CEO of PredxBio, stated, "With Brad's extensive expertise in driving commercial excellence and his proven track record of executing strategies at scale, he is the perfect candidate to lead our global commercial team in the upcoming phase of growth. His leadership will be instrumental in taking our proprietary Explainable AI-powered Spatial Biology analytics solutions to new heights of adoption in the biopharma industry. Having successfully grown businesses for renowned life science and biopharma companies over the past two decades, Brad brings invaluable experience to our team and his appointment as Chief Commercial Officer positions the company for accelerated growth, forging impactful partnerships, and furthering the adoption of innovative solutions in spatial biology and cutting-edge analytics!"
Brad Spitz is a highly accomplished and versatile executive in the life sciences industry, with a wealth of experience across various sectors including biotech, pharmaceuticals, molecular diagnostics, academia, digital pathology, AI, and oncology healthcare. His impressive career includes a 19-year tenure at Johnson & Johnson, where he held roles in multiple operating companies such as Ethicon, Ortho-Clinical Diagnostics, Veridex, and Janssen Diagnostics. During his time at Johnson & Johnson, Brad played a pivotal role in pioneering CellSearch©, one of the earliest liquid biopsy tests in oncology designed to measure circulating tumor cells. Brad has also held Vice President of Sales positions at esteemed companies such as ANGLE Plc., Orbis Biosciences (Acquired by Adare Pharma Solutions), and Congenica, showcasing his expertise in driving sales growth and building successful commercial strategies. In addition to his industry experience, Brad has been involved with the prestigious Mayo Clinic as part of the BioPharma Dx team and most recently served at PaigeAI. Brad holds an MBA from Elon University and a bachelor's degree with double majors in Economics and Communications from the University of Wisconsin, Madison.
"This is an incredibly exciting moment for me as I join the remarkable team at PredxBio and become an integral part of their mission. I am thrilled to have the opportunity to bring this game-changing Spatial Biology technology to the market in a truly transformational way," said Brad Spitz. "Integrity, resiliency, and building great relationships will be at the core of my efforts to help grow this company. I am deeply passionate about leading the fight against cancer, and I cannot wait to collaborate with our key stakeholders at PredxBio and our BioPharma partners to leverage the power of spatial biology in delivering innovative therapies that will positively impact the lives of patients. I am honored to be a part of this journey and look forward to bringing our pioneering solutions to the market as we unlock the true power of spatial biology."
The PredxBio platform seamlessly integrates multimodal data, such as spatial proteomics, spatial transcriptomics, and brightfield pathology, to uncover the hidden circuitries of tumor microenvironments and reveal the complex network biology of cancer. By performing highly scalable, Explainable AI (xAI) powered spatial analyses of diverse imaging techniques, PredxBio generates actionable insights for biomarker discovery, identifying drug targets, and designing effective clinical trials. Through the quantification of cell-cell interactions, identification of intermediate cell types and states, and discovery of microdomains, PredxBio delves into the organizing principles of spatial intratumor heterogeneity, providing a mechanistic understanding of tumor initiation, progression, and response to therapy. This comprehensive platform drives personalized therapeutic options, improving prediction accuracies based on spatial tumor biology and enabling optimal treatment selection for individual patients. With the launch of the PredxBio brand, we establish our leadership position in Spatial Biology, uniquely capable of predicting patient outcomes with 90%+ accuracy by unraveling the hidden biological circuitries of cancer.
About PredxBio
PredxBio is a Pittsburgh, PA-based company focused on the development of explainable AI-powered spatial analytics software platforms to decipher the complex cancer biology and bend the survival curve for immunotherapy cancer patients. PredxBio's solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. PredxBio has already completed engagements with early paying customers including pharma partners who are harnessing PredxBio's solutions to assess treatment response in immunotherapy.
Media Contact
S. Chakra Chennubhotla, PredxBio, 1 4122123115, [email protected]
SOURCE PredxBio
Share this article